The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
about
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavirSaquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administrationGenotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolatesGenetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitorIn vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysisThe effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects.Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.Significant interactions with new antiretrovirals and psychotropic drugs.Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteersDiscontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg.Pharmacologic considerations for therapeutic success with antiretroviral agents.Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.HIV-1 protease inhibitors.The effect of garlic supplements on the pharmacokinetics of saquinavir.Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adultsPharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.Intracellular accumulation of human immunodeficiency virus protease inhibitorsThe role of therapeutic drug monitoring in treatment of HIV infection.Role of therapeutic drug monitoring for protease inhibitors.Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potencyPharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphologySaquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.Effectiveness of highly active antiretroviral therapy among HIV-1 infected womenGrapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in manTherapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinicSaquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention.Updated clinical pharmacologic considerations for HIV-1 protease inhibitors.Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.Converting cancer therapies into cures: lessons from infectious diseases
P2860
Q28344594-00A37555-E22A-4C3B-8312-5712AD062D57Q28345258-CF024C9A-D92D-43EE-B071-B63E48202B9CQ28354163-EF22E8B6-4BBB-4647-8DC9-140D5CB09384Q28369030-B98E143D-C419-4DFE-AF02-A50BBC1805FDQ28379223-0C131CF7-A67E-4341-AB74-36264E43AD6CQ28379356-DE910684-B7DC-4769-A40E-B5AD3FDF9581Q28486262-BDAC1120-B997-42C9-AD6F-8A8DC7F46071Q30692710-C7E2EFEE-35E3-4FB2-B806-21D404570FC3Q31106166-34E3D270-74E3-4A88-BED3-4320D7B9EFEBQ33637697-2C6CF0E4-8CED-415A-9C37-BA5E6323AADAQ33700538-ACEF76C0-5CE5-4DBE-8A7A-25E2E611C097Q33735372-E52DEEBE-244D-4689-BDDA-56679CBC8330Q33735400-55A4BC90-A6E5-4804-B796-08E1DA420F97Q33804495-E5AF1B0D-5BFD-4A63-B702-028CF11744B5Q33906239-D881CC8D-E7E0-4113-B59E-85298D1E70D1Q33946915-3435474B-1B8D-41D2-BE44-3E101DD4DE97Q33946920-AD6A66C3-1E0C-4D9E-A2F2-3327305138A0Q33956369-69296C9B-9892-4830-843F-4515B46BDE4DQ33980711-43EFD757-588D-44C2-AEC7-D303E3D4A186Q34113462-32F84176-EAC7-4DBD-B8A7-84695D266DF7Q34143531-3E4FFB74-66AB-4049-9FA1-C237DF3082DCQ34229283-D6464558-241D-4368-89CA-10154F190B45Q34284286-FB027FC7-3D10-45ED-8901-19DBB9569709Q34537487-A0850576-E515-4EA9-95D1-7252C67EB6F3Q34720072-94409AFF-F0A4-4D14-9926-3B23350DAB9DQ35001188-499F2582-5C48-4AC5-A878-7A32BA447BE6Q35134071-E704BF8A-F6A3-4DB9-A67B-F42946821BF7Q35135963-590F112B-42A5-4F69-849B-3C2424B83857Q35137965-6443A430-80A0-4A77-980C-0FB74FF2A22CQ35138883-25D66658-A161-4641-9373-BFF1F6FE3CA3Q35138891-2DD8F686-E1E3-4F3B-89B7-D61C8105AEBFQ35196290-3CA3BF4D-D5D1-46D2-B3D3-CDA41E93D45CQ35407246-D6788F01-7256-44E3-88C4-4B7830114670Q35803002-C6FCFBF0-CC4B-4EE3-A464-93EDE698190FQ35826064-87DEFBC5-4355-4323-B8A8-857DF6BA9850Q35826795-D2844987-26D1-47B6-8B02-E7081C48EBFAQ36171647-3F1BF6E8-4B8B-4C01-85A2-B9BB31A0D46DQ36223724-E0BF1440-55B1-42EA-96E0-F2BF1D32E214Q36246775-6C42427D-1C45-45FD-BD5F-879133A70C23Q36301709-5DBE30BD-C621-46A0-A9E1-4D673C63A79A
P2860
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
The effect of high-dose saquin ...... unts in HIV-infected patients.
@en
The effect of high-dose saquin ...... unts in HIV-infected patients.
@nl
type
label
The effect of high-dose saquin ...... unts in HIV-infected patients.
@en
The effect of high-dose saquin ...... unts in HIV-infected patients.
@nl
prefLabel
The effect of high-dose saquin ...... unts in HIV-infected patients.
@en
The effect of high-dose saquin ...... unts in HIV-infected patients.
@nl
P2093
P1476
The effect of high-dose saquin ...... ounts in HIV-infected patients
@en
P2093
P304
P356
10.7326/0003-4819-124-12-199606150-00003
P407
P577
1996-06-01T00:00:00Z